Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study)

American Heart Journal

Volumn 146, Issue 4, 2003, Pages 668-673

  Huynh, Thao ^a   Theroux, Pierre ^b   Snapinn, Steven ^c   Wan, Ying ^c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING TENDENCY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG SAFETY; EARLY DIAGNOSIS; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0142057093     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00255-2     Document Type: Article

References (26)

1. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
2. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N Engl J Med 1998;338:1488-97.
3. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor) or heparin, or both in unstable angina: platelet IIb/IIIa Antagonism for the Reduction of Acute coronary events in a Global Organization Network. Circulation 1998;97:2386-95.
4. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
5. Cheesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142-54.
6. Antman E, Cohen M, Bernink P, et al. The TIMI risk score for unstable angina/non-ST-elevation myocardial infarction. JAMA 2000;284:835-42.
7. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975;253:353-7.
8. Faraday N, Goldschmidt-Clermont PJ, Bray P. Gender differences in platelet GPIIb/IIIa activation. Thromb Haemost 1997;77:748-54.
9. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. J Am Coll Cardiol 2000;35:381-6.
10. Fernandes LS, Tcheng JE, O'Shea JC, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J Am Coll Cardiol 2002:401085-91.
11. Lincoff AM, Harrington RA, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy (PURSUIT) Trial. Circulation 2000;102:1093-100.
12. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE trial. Lancet 1997;349:1429-35.
13. Lincoff AM, Califf RM, Andersen KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary intervention. J Am Coll Cardiol 1997;30:149-56.
14. Kleiman NS, Lincoff ML, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 2000;101:751-7.
15. IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;3349:1422-8.
16. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356:2037-44.
17. Boersma E, Akkerhuis M, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100:2045-8.
18. Hochman JS, Tams JE, Thompson TD. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med 1999;341:226-32.
19. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-Segment elevation: results from an international trial of 9461 patients. Circulation 2000;101:2557-67.
20. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002;359:189-98.
21. GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
22. Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. Circulation 2000;102:1101-6.
23. Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. J Am Coll Cardiol 1997;30:1141-8.
24. Scirica BM, Moliterna DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (the GUARANTEE Registry). Am J Cardiol 1999;84:1145-50.
25. Zhao XQ, Theroux P, Snapinn SM, et al. Intracoronary thrombus and platelet glycoprotein IIB/IIIa receptor blockade with tirofiban in unstable angina or non-Q-Wave myocardial infarction. Circulation 1999;100:1609-15.
26. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.